Celcuity (NASDAQ:CELC) Price Target Raised to $24.00

Celcuity (NASDAQ:CELCFree Report) had its price target upped by Needham & Company LLC from $23.00 to $24.00 in a research note released on Thursday, Benzinga reports. Needham & Company LLC currently has a buy rating on the stock.

A number of other equities research analysts have also recently commented on CELC. HC Wainwright reiterated a buy rating and issued a $27.00 price target on shares of Celcuity in a research note on Thursday. Stifel Nicolaus assumed coverage on Celcuity in a research note on Thursday, February 22nd. They issued a buy rating and a $40.00 price target for the company.

Get Our Latest Stock Analysis on CELC

Celcuity Trading Up 18.9 %

Celcuity stock opened at $21.60 on Thursday. The stock has a 50-day moving average of $16.47 and a two-hundred day moving average of $13.68. The company has a debt-to-equity ratio of 0.26, a quick ratio of 11.15 and a current ratio of 13.43. Celcuity has a one year low of $8.39 and a one year high of $22.19. The stock has a market cap of $522.72 million, a PE ratio of -8.03 and a beta of 0.74.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the company. Morgan Stanley increased its holdings in shares of Celcuity by 23.5% in the third quarter. Morgan Stanley now owns 1,967,776 shares of the company’s stock valued at $17,985,000 after purchasing an additional 374,196 shares during the period. Commodore Capital LP grew its holdings in Celcuity by 3.6% during the fourth quarter. Commodore Capital LP now owns 1,754,704 shares of the company’s stock worth $25,566,000 after acquiring an additional 60,563 shares during the period. Perceptive Advisors LLC acquired a new stake in Celcuity during the fourth quarter worth about $21,583,000. Soleus Capital Management L.P. grew its holdings in Celcuity by 172.6% during the fourth quarter. Soleus Capital Management L.P. now owns 1,210,228 shares of the company’s stock worth $16,955,000 after acquiring an additional 766,316 shares during the period. Finally, BlackRock Inc. grew its holdings in Celcuity by 599.7% during the second quarter. BlackRock Inc. now owns 912,972 shares of the company’s stock worth $10,024,000 after acquiring an additional 782,486 shares during the period. 63.33% of the stock is owned by institutional investors and hedge funds.

About Celcuity

(Get Free Report)

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.

Recommended Stories

Receive News & Ratings for Celcuity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celcuity and related companies with MarketBeat.com's FREE daily email newsletter.